- NMP22
-
NMP22 is a tumor marker for bladder cancer.[1][2][3]
References
- ^ Kumar A, Kumar R, Gupta NP (March 2006). "Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer". Jpn. J. Clin. Oncol. 36 (3): 172–5. doi:10.1093/jjco/hyi244. PMID 16520358. http://jjco.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=16520358.
- ^ Moonen PM, Kiemeney LA, Witjes JA (December 2005). "Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer". Eur. Urol. 48 (6): 951–6; discussion 956. doi:10.1016/j.eururo.2005.09.002. PMID 16257108. http://linkinghub.elsevier.com/retrieve/pii/S0302-2838(05)00579-8.
- ^ Bassi P, De Marco V, De Lisa A, et al. (2005). "Non-invasive diagnostic tests for bladder cancer: a review of the literature". Urol. Int. 75 (3): 193–200. doi:10.1159/000087792. PMID 16215303. http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=UIN2005075003193.
Tumor markers Blood LymphosarcomaEndocrine Nervous system Cardiovascular/
respiratoryDigestive Reproductive/
urinary/
breastSurface epithelial-stromal tumor (CA-125) · EC (CD30, hCG) · EST (Alpha-fetoprotein) · Choriocarcinoma (hCG) · Dysgerminoma (LDH) · Sertoli-Leydig cell tumour (Testosterone) · GCT (Inhibin)erbB-3 receptor · NMP22General histology Musculoskeletal M: NEO
tsoc, mrkr
tumr, epon, para
drug (L1i/1e/V03)
Categories:- Tumor markers
- Biochemistry stubs
Wikimedia Foundation. 2010.